CELC · Celcuity Inc.
$65.25
-0.49% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-815.6
Dividend yield
0.0%
Beta
0.11
Avg volume
1M
Employees
0K
Daily Change %
-0.49%
5 Days Change
15.89%
10 Days Change
3.77%
30 Days Change
-18.03%
60 Days Change
-27.78%
Month to Day Change
-12.72%
Year to Day Change
-34.26%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CELC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
JP Morgan
Overweight$157
+140.6% vs priceWells Fargo
Overweight$166
+154.4% vs priceJefferies
Buy$134
+105.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $140 |
| 2026-10-21 | TD Cowen | Reiterates | Buy | $0.00 → $145 |
| 2026-09-30 | Needham | Maintains | Buy | $140 → $134 |
| 2026-09-17 | JP Morgan | Initiates | Overweight | $0.00 → $157 |
| 2026-08-17 | Guggenheim | Maintains | Buy | $165 → $175 |
| 2026-08-17 | Citizens | Reiterates | Market Outperform | $177 |
| 2026-08-14 | HC Wainwright & Co. | Reiterates | Buy | $155 |
| 2026-08-14 | Stifel | Maintains | Buy | $175 → $150 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 18.5% below the 50-day MA ($80.07).
- bearish: Price vs 200-day MA: Trading 35.8% below the 200-day MA ($101.60).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.62) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($56.58) and high ($144.98).
CELC Price Chart
Loading chart for CELC…
Fundamentals
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.